Pablo Catalán Serra

Pablo Catalán Serra

Auto-generated profile, based on publicly available information

Pablo Catalán Serra

Servicio de Neumología, Hospital Universitario Doctor Peset, Valencia, España

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MMMiguel Angel Martinez-Garcia
Miguel Angel Martinez-Garcia
DRDavid De la Rosa-Carrillo
David De la Rosa-Carrillo
JSJuan-Jose Soler-Cataluña
Juan-Jose Soler-Cataluña
YDYolanda Donat-Sanz
Yolanda Donat-Sanz
PSPablo Catalán Serra
Pablo Catalán Serra
MVMontserrat Bertomeu Valdecillos
Montserrat Bertomeu Valdecillos
Rationale: The prevalence of bronchiectasis is high in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and it has been associated with exacerbations and bacterial colonization. These have demonstrated some degree of prognostic value in patients with COPD but no information about the relationship between bronchiectasis and mortality in patients with COPD is currently available. Objectives: To assess the prognostic value of bronchiectasis in patients with moderate-to-severe COPD. Methods: Multicenter prospective observational study in consecutive patients with moderate-to-severe COPD. Bronchiectasis was diagnosed by high-resolution computed tomography scan. A complete standardized protocol was used in all patients covering general, anthrophometric, functional, clinical, and microbiologic data. After follow-up, the vital status was recorded in all patients. Multivariate Cox analysis was used to determine the independent adjusted prognostic value of bronchiectasis. Measurements and Main Results: Ninety-nine patients in Global Initiative for Chronic Obstructive Lung Disease (GOLD) II, 85 in GOLD III, and 17 in GOLD IV stages were included. Bronchiectasis was present in 115 (57.2%) patients. During the follow-up (median, 48 mo [interquartile range, 35–53]) there were 51 deaths (43 deaths in the bronchiectasic group). Bronchiectasis was associated with an increased risk of fully adjusted mortality (hazard ratio, 2.54; 95% confidence interval, 1.16–5.56; P = 0.02). Conclusions: Bronchiectasis was associated with an independent increased risk of all-cause mortality in patients with moderate-to-severe COPD.

1 November 2012 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MMMiguel Angel Martinez-Garcia
Miguel Angel Martinez-Garcia
FGFrancisco Garcia-Rio
Francisco Garcia-Rio
PCPablo Catalán-Serra
Pablo Catalán-Serra
JSJuan-José Soler-Cataluña
Juan-José Soler-Cataluña
CACarmen Almeida-Gonzalez
Carmen Almeida-Gonzalez
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat
Rationale: Obstructive sleep apnea (OSA) is a risk factor for cardiovascular death in middle-aged subjects, but it is not known whether it is also a risk factor in the elderly. Objectives: To investigate whether OSA is a risk factor for cardiovascular death and to assess whether continuous positive airway pressure (CPAP) treatment is associated with a change in risk in the elderly. Methods: Prospective, observational study of a consecutive cohort of elderly patients (≥65 yr) studied for suspicion of OSA between 1998 and 2007. Patients with an apnea–hypopnea index (AHI) less than 15 were the control group. OSA was defined as mild to moderate (AHI, 15–29) or severe (AHI, ≥30). Patients with OSA were classified as CPAP-treated (adherence ≥ 4 h/d) or untreated (adherence < 4 h/d or not prescribed). Participants were monitored until December 2009. The end point was cardiovascular death. A multivariate Cox survival analysis was used to determine the independent impact of OSA and CPAP treatment on cardiovascular mortality. Measurements and Main Results: A total of 939 elderly were studied (median follow-up, 69 mo). Compared with the control group, the fully adjusted hazard ratios for cardiovascular mortality were 2.25 (confidence interval [CI], 1.41 to 3.61) for the untreated severe OSA group, 0.93 (CI, 0.46 to 1.89) for the CPAP-treated group, and 1.38 (CI, 0.73 to 2.64) for the untreated mild to moderate OSA group. Conclusions: Severe OSA not treated with CPAP is associated with cardiovascular death in the elderly, and adequate CPAP treatment may reduce this risk.

1 November 2011 in Chest
Verified
Journal Article
Closed access
PDF file
MMMiguel Ángel Martínez-García
Miguel Ángel Martínez-García
JSJuan José Soler-Cataluña
Juan José Soler-Cataluña
YSYolanda Donat Sanz
Yolanda Donat Sanz
PSPablo Catalán Serra
Pablo Catalán Serra
MLMarcos Agramunt Lerma
Marcos Agramunt Lerma
MPMiguel Perpiñá-Tordera
Miguel Perpiñá-Tordera

15 June 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
FGFrancisco Garcia-Rio
Francisco Garcia-Rio
MMMiguel A. Martinez-Garcia
Miguel A. Martinez-Garcia
NRNuria Reyes-Nuñez
Nuria Reyes-Nuñez
ICIsabel Caballero-Martinez
Isabel Caballero-Martinez
PCPablo Catalan-Serra
Pablo Catalan-Serra
CACarmen V. Almeida-Gonzalez
Carmen V. Almeida-Gonzalez
Rationale: It is unknown whether obstructive sleep apnea (OSA) may be a risk factor for incident cardiovascular events in women. Objectives: We sought to investigate whether OSA increases the incidence of a composite of stroke or coronary heart disease (CHD) in women, and the role of continuous positive airway pressure (CPAP) treatment on this association. Methods: This was a prospective, observational study conducted in two Spanish teaching hospitals between 1998 and 2007. Consecutive women referred for suspected OSA and free of previous stroke and CHD were analyzed. Women with an apnea–hypopnea index (AHI) less than 10 comprised the control group, and those with an AHI greater than or equal to 10 were diagnosed with OSA and classified as CPAP-treated (adherence ≥ 4 h/d) or untreated (adherence < 4 h/d or not prescribed). The follow-up ended in December 2010. Measurements and Main Results: A total of 967 women were studied (median follow-up, 6.8 yr; interquartile range, 5.2–8.2). The untreated OSA group showed a greater incidence rate of the composite outcome than the control group (2.19 vs. 0.54 per 100 person-years; P < 0.0005). Compared with the control group, the fully adjusted hazard ratios for the composite outcome incidence were 2.76 (95% confidence interval [CI], 1.35–5.62) for the untreated OSA group, and 0.91 (95% CI, 0.43–1.95) for the CPAP-treated group. When the type of cardiovascular event was separately assessed, untreated OSA showed a stronger association with incident stroke (adjusted hazard ratio, 6.44; 95% CI, 1.46–28.3) than with CHD (adjusted hazard ratio, 1.77; 95% CI, 0.76–4.09). Conclusions: In women, untreated OSA is associated with increased incidence of serious cardiovascular outcomes, particularly incident stroke. Adequate CPAP treatment seems to reduce this risk.

1 July 2014 in Sleep Medicine
Verified
Journal Article
Closed access
MMMiguel Angel Martinez-Garcia
Miguel Angel Martinez-Garcia
FGFrancisco Garcia-Rio
Francisco Garcia-Rio
JDJoaquín Durán-Cantolla
Joaquín Durán-Cantolla
MPMónica de la Peña
Mónica de la Peña
MMMaría J. Masdeu
María J. Masdeu
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat

29 September 2011 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MMM-A. Martínez-García
M-A. Martínez-García
FGFrancisco Garcia-Rio
Francisco Garcia-Rio
JSJ-J. Soler-Cataluña
J-J. Soler-Cataluña
PCP. Catalán-Serra
P. Catalán-Serra
PRP. Román-Sánchez
P. Román-Sánchez
JMJavier Marcelo Montserrat
Javier Marcelo Montserrat
Obstructive sleep apnoea (OSA) is a risk factor for stroke, but little is known about the effect of OSA and continuous positive airway pressure (CPAP) on the incidence of long-term, nonfatal cardiovascular events (CVE) in stroke patients.A prospective observational study was made in 223 patients consecutively admitted for stroke. A sleep study was performed on 166 of them. 31 had an apnoea/hypopnoea index (AHI) <10 events·h−1; 39 had an AHI between 10 and 19 events·h−1and 96 had an AHI ≥20 events·h−1. CPAP treatment was offered when AHI was ≥20 events·h−1. Patients were followed up for 7 yrs and incident CVE data were recorded.The mean±sdage of the subjects was 73.3±11 yrs; mean AHI was 26±16.7 events·h−1. Patients with moderate-to-severe OSA who could not tolerate CPAP (AHI ≥20 events·h−1; n=68) showed an increased adjusted incidence of nonfatal CVE, especially new ischaemic strokes (hazard ratio 2.87, 95% CI 1.11–7.71; p=0.03), compared with patients with moderate-to-severe OSA who tolerated CPAP (n=28), patients with mild disease (AHI 10–19 events·h−1; n=36) and patients without OSA (AHI <10 events·h−1; n=31).Our results suggest that the presence of moderate-to-severe OSA is associated with an increased long-term incidence of nonfatal CVE in stroke patients and that CPAP reduces the excess of incidence seen in these patients.